0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > CTLA-4

CTLA-4

Brief Information

Name:Cytotoxic T-Lymphocyte-Associated Antigen 4
Target Synonym:Celiac Disease 3,Ligand And Transmembrane Spliced Cytotoxic T Lymphocyte Associated Antigen 4,Cytotoxic T-Lymphocyte Protein 4,CD152,Cytotoxic T-lymphocyte-associated antigen 4,CTLA4,CTLA-4,Cytotoxic T-Lymphocyte Associated Protein 4,Insulin-Dependent Diabetes Mellitus 12,Cytotoxic T Lymphocyte Associated Antigen 4 Short Spliced Form,Cytotoxic T-Lymphocyte-Associated Serine Esterase-4,CD152 Isoform,CD152 Antigen,CELIAC3,IDDM12,ALPS5,GRD4,GSE,CD,CTLA-4 Antigen
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:61
Lastest Research Phase:Approved

Product ListCompare or Buy

Cat . Non Espèces Description du produit Structure Pureté Caractéristique
CT4-HP2H3 Human PE-Labeled Human CTLA-4 / CD152 Protein, His TagStar Staining
CT4-C82F3 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque CTLA-4 Protein, Fc,Avitag™ (MALS verified)
CT4-C82F3-structure
CT4-C82F3-sds
CT4-M82F3 Mouse Biotinylated Mouse CTLA-4 / CD152 Protein, Fc,Avitag™ (MALS verified)
CT4-M82F3-structure
CT4-M82F3-sds
CT4-R52H6 Rat Rat CTLA-4 / CD152 Protein, His Tag
CT4-R52H6-structure
CT4-R52H6-sds
CT4-R52H4 Rabbit Rabbit CTLA-4 / CD152 Protein, His Tag
CT4-R52H4-structure
EP-117 Human B7-2 [Biotinylated] : CTLA-4 Inhibitor Screening ELISA Kit
EP-126 Human CTLA-4 [Biotinylated] : B7-2 Inhibitor Screening ELISA Kit
EP-116 Human B7-1 [Biotinylated] : CTLA-4 Inhibitor Screening ELISA Kit
MBS-K042 Human Human CTLA-4 coupled Magnetic Beads
CT4-H52H9 Human Human CTLA-4 / CD152 Protein, His Tag, active dimer (MALS verified)
CT4-H52H9-sds
CT4-H82E3 Human Biotinylated Human CTLA-4 Protein, His,Avitag™ (MALS verified)
CT4-H82E3-structure
CT4-H82E3-sds
CT4-M82E7 Mouse Biotinylated Mouse CTLA-4 Protein, His,Avitag™
CT4-M82E7-structure
CT4-M82E7-sds
CT4-H82E1 Human Biotinylated Human CTLA-4 Protein, His,Avitag™
CT4-H82E1-structure
CT4-H82E1-sds
CT4-H52A4 Human Human CTLA-4 / CD152 Protein, mouse IgG2a Fc Tag, low endotoxin
CT4-H52A4-structure
CT4-H52A4-sds
CT4-R5250 Rabbit Rabbit CTLA-4 / CD152 Protein, Fc Tag
CT4-R5250-structure
CT4-R5250-sds
CT4-R5259 Rat Rat CTLA-4 / CD152 Protein, Fc Tag (MALS verified)
CT4-R5259-structure
CT4-R5259-sds
CT4-M5256 Mouse Mouse CTLA-4 / CD152 Protein, Fc Tag (MALS verified)
CT4-M5256-structure
CT4-M5256-sds
CT4-M52H5 Mouse Mouse CTLA-4 / CD152 Protein, His Tag (MALS verified)
CT4-M52H5-structure
CT4-M52H5-sds
CT4-H82F3 Human Biotinylated Human CTLA-4 Protein, Fc,Avitag™
CT4-H82F3-structure
CT4-H82F3-sds
CT4-C82E5 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque CTLA-4 Protein, Avitag™,His Tag
CT4-C82E5-structure
CT4-C82E5-sds
CT4-H5284 Human Human CTLA-4 / CD152 Protein, Twin-Strep Tag
CT4-H5284-structure
CT4-H5284-sds
CT4-C5227 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CTLA-4 Protein, His Tag (MALS verified)
CT4-C5227-structure
CT4-C5227-sds
CT4-C5256 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CTLA-4 Protein, Fc Tag (MALS verified)
CT4-C5256-structure
CT4-C5256-sds
CT4-H5255 Human Human CTLA-4 / CD152 Protein, Fc Tag (MALS verified)
CT4-H5255-structure
CT4-H5255-sds
CT4-H5229 Human Human CTLA-4 / CD152 Protein, His Tag
CT4-H5229-structure
CT4-H5229-sds
ACRO Quality

Part of Bioactivity data

CT4-HP2H3-Cell-based assay
 CTLA-4 FACS

Flow cytometric analysis of Raji cells staining with PE-Labeled Human CTLA-4 Protein, His Tag (Cat. No. CT4-HP2H3) at 1:50 dilution (2μL of the antibody stock solution corresponds to labeling of 5e5 cells in a final volume of 100 µL) , compared with negative control protein. PE signal was used to evaluate the binding activity(QC tested).

CT4-H82E3-SPR
 CTLA-4 SPR

Biotinylated Human CTLA-4, His,Avitag (Cat. No. CT4-H82E3) captured on Biotin CAP - Series S sensor Chip can bind Yervoy (Ipilimumab) with an affinity constant of 0.635 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

CT4-H5229-SPR
 CTLA-4 SPR

Yervoy (Ipilimumab, Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CTLA-4, His Tag (Cat. No. CT4-H5229) with an affinity constant of 25.7 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Customer Reviews

Synonym Name

CTLA4,CD152

Background

CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is also known as CD152 (Cluster of differentiation 152), is a protein receptor that downregulates the immune system. CTLA4 is a member of the immunoglobulin superfamily, which is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. T cell activation through the T cell receptor and CD28 leads to increased expression of CTLA-4, an inhibitory receptor for B7 molecules. Fusion proteins of CTLA4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Cadonilimab AK-104; AK104 Approved Zhongshan Akeso Biopharma Co Ltd 开坦尼 Mainland China Uterine Cervical Neoplasms Kangfang Pharmaceutical Co Ltd 2022-06-29 Nasopharyngeal Carcinoma; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Uterine Cervical Neoplasms; Esophageal Squamous Cell Carcinoma; DNA Repair-Deficiency Disorders; Urologic Neoplasms; Colorectal Neoplasms; Vulvar Neoplasms; Microsatellite Instability; Solid tumours; Microsatellite instability-high cancer; Triple Negative Breast Neoplasms; Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Vaginal Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma; Esophageal Neoplasms; Lymphoma, T-Cell, Peripheral Details
Ipilimumab 10D1; MDX-CTLA-4; Anti-CTLA-4 Mab; BMS-734016; Mab-10D14; MDX-101; MDX-010 Approved Bristol-Myers Squibb Company Yervoy, 逸沃 United States Melanoma Bristol-Myers Squibb Company 2011-03-25 Primary Myelofibrosis; Brain metastases; Neoplasms, Gonadal Tissue; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Burkitt Lymphoma; Testicular Neoplasms; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Colorectal Neoplasms; Sezary Syndrome; Sarcoma; Neuroblastoma; Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Uterine Cervical Neoplasms; Endodermal Sinus Tumor; Leukemia, T-Cell; Leukemia, Large Granular Lymphocytic; Adenocarcinoma; Leukemia, Lymphocytic, Chronic, B-Cell; Mycosis Fungoides; Carcinoma, Hepatocellular; Prostatic Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Embryonal; Choriocarcinoma; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Intraocular Lymphoma; Lymphoma, T-Cell; Squamous Cell Carcinoma of Head and Neck; Carc Details
Tremelimumab CP-675206; CP-675 Approved Pfizer Inc IMJUDO United States Carcinoma, Hepatocellular Astrazeneca Ab 2022-10-21 Urogenital Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Vulvar Neoplasms; Urethral Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Oropharyngeal Neoplasms; Ureteral Neoplasms; Peritoneal Neoplasms; Genital Neoplasms, Female; Carcinoma, Squamous Cell; Mouth Neoplasms; Prostatic Neoplasms; Gallbladder Neoplasms; Esophageal adenocarcinoma; Glioma; Lung Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Hepatitis C, Chronic; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Endometrioid; Cystadenoma, Serous; Solid tumours; Head and Neck Neoplasms; Hematologic Neoplasms; Bone metastases; Kidney Neoplasms; Biliary Tract Neoplasms; Ovarian Neoplasms; HIV Infections; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Vaginal Neoplasms; Carcinoma; Liver Neoplasms; Cystadenocarcinoma, Serous; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Neopl Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CS-1002 SHR-8068; CS-1002 Phase 3 Clinical Cstone Pharmaceuticals Solid tumours; Stomach Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung Details
Botensilimab AGEN-1181 Phase 3 Clinical Agenus Inc Colonic Neoplasms; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Adenocarcinoma; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Esophageal adenocarcinoma; Colorectal Neoplasms; Prostatic Neoplasms; Microsatellite Instability; Solid tumours; Pancreatic Neoplasms; Neoplasms; Fibrolamellar hepatocellular carcinoma; Rectal Neoplasms; Carcinoma, Renal Cell; Hemangiosarcoma; Stomach Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms; Liver Neoplasms Details
Gotistobart ONC-392; BNT316; BNT-316 Phase 3 Clinical Oncoimmune Inc Carcinoma, Adenoid Cystic; Uterine Cervical Neoplasms; Adenocarcinoma; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Sarcoma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Ovarian Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Salivary Gland Neoplasms; Pancreatic Neoplasms; Cystadenocarcinoma, Serous; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Anorectal disorders; Solid tumours; Head and Neck Neoplasms Details
Erfonrilimab KN046; KN-046 Phase 3 Clinical Jiangsu Alphamab Biopharmaceuticals Co Ltd Colorectal Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Thymoma; Esophageal Squamous Cell Carcinoma; Lymphoma; Solid tumours; Thymus Neoplasms; Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Biliary Tract Neoplasms Details
Volrustomig MEDI-5752; MEDI5752 Phase 3 Clinical Medimmune Llc Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma, Renal Cell; Mesothelioma; Sarcoma; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular Details
BCD-217 BCD-217 Phase 3 Clinical Biocad Melanoma Details
Ipilimumab biosimilar (Innovent Biologics) IBI-310 Phase 3 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Biliary Tract Neoplasms; Liver Neoplasms; Esophageal Neoplasms; Colonic Neoplasms; Neuroendocrine Tumors; Nasopharyngeal Carcinoma; Microsatellite Instability; Colorectal Neoplasms; Bile Duct Neoplasms; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Pembrolizumab/Quavonlimab MK-1308A Phase 3 Clinical Merck Sharp & Dohme Corp, Msd Ireland (Carlow), MSD R&D(China)Co Ltd Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma Details
YH-001 YH-001 Phase 2 Clinical Eucure Pharmaceutical Technology (Beijing) Co Ltd Liver Neoplasms; Solid tumours; Alopecia Areata; Sarcoma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
SI-B003 SI-B003 Phase 2 Clinical Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Breast Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma Details
BMS-986288 BMS-986288 Phase 2 Clinical Cytomx Therapeutics Inc Neoplasms Details
Evalstotug CAB-CTLA-4; BA-3071 Phase 2 Clinical Bioatla, Beigene Ltd Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular Details
Vudalimab XmAb-20717; XmAb-717; XmAb 717 Phase 2 Clinical Xencor Inc Thymoma; Adenocarcinoma, Clear Cell; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Vulvar Neoplasms; Prostatic Neoplasms; Astrocytoma; Colorectal Neoplasms; Endometrial Neoplasms; Microsatellite instability-high cancer; Carcinoma, Neuroendocrine; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Ovarian Epithelial; Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma, Basal Cell; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Hodgkin Disease; Adenoma, Acidophil; Colonic Neoplasms; Mesothelioma; Adnexal Diseases; Prostatic Neoplasms, Castration-Resistant Details
Recombinant anti-CTLA-4 human monoclonal antibody (Hualan Biological Engineering) Phase 2 Clinical Hualan Genetic Engineering Co Ltd Melanoma Details
Lorigerlimab MGD-019; AEX1344 Phase 2 Clinical Macrogenics Inc Solid tumours; Liver Neoplasms; Skin Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung Details
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) Phase 2 Clinical Changhai Hospital Of Shanghai Pancreatic Neoplasms Details
RP-2 RP-2 Phase 2 Clinical Replimune Group Inc, Bristol-Myers Squibb Company Neoplasms; Colorectal Neoplasms Details
Abatacept (Orban Biotech) Phase 2 Clinical Orban Biotech, The National Institute Of Diabetes And Digestive And Kidney Diseases Diabetes Mellitus, Type 1 Details
Quavonlimab MK-1308; AK-107 Phase 2 Clinical Zhongshan Akeso Biopharma Co Ltd, Merck Sharp & Dohme Corp Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Zalifrelimab AGEN-1884; RebmAb-600; UGN-301 Phase 2 Clinical 4-Antibody, Ludwig Institute For Cancer Research Solid tumours; Carcinoma; Hemangiosarcoma; Urinary Bladder Neoplasms; Sarcoma; Urologic Neoplasms; Carcinoma, Pancreatic Ductal; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details
BMS-986218 (Bristol-Myers Squibb) BMS-986218 Phase 2 Clinical Bristol-Myers Squibb Company Solid tumours; Liver Neoplasms; Adrenal Gland Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Lung Neoplasms Details
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) Phase 2 Clinical Shanghai Cell Therapy Research Institute Neoplasms Details
KD-6001 KD-6001 Phase 2 Clinical Shanghai Kanda Bio-Technology Co Ltd, Shanghai Celgen Bio-Pharmaceutical Co Ltd Liver Neoplasms; Solid tumours; Neoplasms; Melanoma; Carcinoma, Hepatocellular Details
BT-001 BT-001 Phase 2 Clinical Transgene Sa Carcinoma, Merkel Cell; Triple Negative Breast Neoplasms; Neoplasms; Sarcoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Porustobart HBM-4003; HCAb 4003-2 Phase 2 Clinical Harbour Biomed Solid tumours; Neoplasms; Neuroendocrine Tumors; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
JK-08 JK-08 Phase 2 Clinical Xinlitai (Chengdu) Biological Technology Co Ltd Small Cell Lung Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma; Carcinoma, Squamous Cell; Thyroid Neoplasms; Colorectal Neoplasms; Carcinoma, Ovarian Epithelial; Solid tumours; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms Details
Sovipostobart BMS-986249 Phase 2 Clinical Cytomx Therapeutics Inc Neoplasms Details
GI-101 SIM-323; SIM323; GI-101 Phase 2 Clinical GI Innovation Inc Solid tumours; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Vaginal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Vulvar Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis Details
Firastotug ADG-116 Phase 2 Clinical Adagene (Suzhou) Ltd Solid tumours; Neoplasms; Neoplasm Metastasis Details
COYA-302 COYA302; COYA 302; COYA-302 Phase 2 Clinical Coya Therapeutics Inc Parkinson Disease; Frontotemporal Dementia; Amyotrophic Lateral Sclerosis Details
GI-102 GI-102 Phase 2 Clinical GI Innovation Inc Solid tumours; Neoplasm Metastasis Details
Anti-CTLA-4/PD-1 expressing EGFR-CAR-T Phase 2 Clinical Shanghai Cell Therapy Research Institute Solid tumours Details
XTX-101 XTX-101 Phase 2 Clinical Xilio Development Inc Solid tumours Details
RP-3 RP-3 Phase 2 Clinical Replimune Inc Solid tumours; Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Hepatocellular Details
Muzastotug ADG-126 Phase 2 Clinical Adagene Inc Liver Neoplasms; Solid tumours; Neoplasms; Neoplasm Metastasis Details
PD-L1 antibody combined with CTLA-4 antibody (Shanghai Zhongshan Hospital) Phase 2 Clinical Shanghai Zhongshan Hospital Cholangiocarcinoma Details
JS-007 JS007; JS-007 Phase 2 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Pancreatic Neoplasms; Neoplasms; Lung Neoplasms; Melanoma Details
KN-044 KN-044 Phase 1 Clinical Suzhou Alphamab Co Ltd Solid tumours Details
Bavunalimab XmAb-22841; XmAb-841 Phase 1 Clinical Xencor Inc Cholangiocarcinoma; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Fallopian Tube Neoplasms; Penile Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Prostatic Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck Details
ATOR-1015 ADC-1015; ATOR-1015 Phase 1 Clinical Alligator Bioscience Ab Solid tumours; Neoplasms Details
Anti-CTLA-4 monoclonal antibody (Regeneron) REGN-4659 Phase 1 Clinical Carcinoma, Non-Small-Cell Lung Details
Ipilimumab biosimilar (Henlius) HLX13 Phase 1 Clinical Shanghai Henlius Biotech Inc Liver Neoplasms; Solid tumours; Esophageal Neoplasms; Carcinoma, Renal Cell; Mesothelioma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma Details
Ipilimumab biosimilar (Mab-Venture/ShuangLu Pharmaceutical) MV-049 Phase 1 Clinical Beijing Sl Pharmaceutical Co Ltd, Mab-Venture Biopharm Co Ltd Solid tumours Details
SAL-008 SAL-008 Phase 1 Clinical Xinlitai (Chengdu) Biological Technology Co Ltd Neoplasms Details
GIGA-564 GIGA-564 Phase 1 Clinical GigaGen Inc Solid tumours; Neoplasms Details
A-337 (Klus Pharma) A337 (Klus Pharma); A-337 (Klus Pharma) Phase 1 Clinical Klus Pharma Inc Neoplasms Details
BZE-2209 BZE-2209; BZE2209; αPD1/CTLA4-MSLN-CAR T Cells Phase 1 Clinical Shanghai Cell Therapy Group Co Ltd Solid tumours Details
MT-8421 MT-8421; CTLA-4 ETB Phase 1 Clinical Molecular Templates Inc Squamous Cell Carcinoma of Head and Neck; Mismatch Repair Deficient Cancer; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Microsatellite instability-high cancer; Mesothelioma; Esophageal Squamous Cell Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular Details
STW204/Gotistobart AI-061 Phase 1 Clinical Oncoc4 Inc Colorectal Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Bile Duct Neoplasms; Carcinoma, Renal Cell; Peritoneal Neoplasms; Digestive System Neoplasms; Urinary Bladder Neoplasms; Stomach Neoplasms; Anus Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Cystadenocarcinoma, Serous Details
KM602 KM602; KM-602; XZP-KM602 Phase 1 Clinical Xuanzhu (Shijiazhuang) Biotechnology Co Ltd Solid tumours Details
TG-6050 TG-6050 Phase 1 Clinical Transgene Sa Carcinoma, Non-Small-Cell Lung Details
IMM-27M IMM27M; IMM-27M Phase 1 Clinical ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Solid tumours; Neoplasms; Pathologic Processes Details
TWP-102 TWP-102 Phase 1 Clinical Therawisdom Biopharma Co Ltd Neoplasms Details
SKB-337 SKB337; A-337; SKB-337 Phase 1 Clinical Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Solid tumours Details
CD-200-AR-L CD-200-AR-L; hP-1-A-8 Phase 1 Clinical University Of Minnesota, OX2 Therapeutics Glioblastoma; Glioma Details
BAT-4706 BAT-4706 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours; Melanoma Details
FPT-155 CD80-Fc; FPT-155 Phase 1 Clinical Five Prime Therapeutics Inc Solid tumours Details
B7-2/GM-CSF cancer gene therapy CIT Phase 1 Clinical Radient Neoplasms Details

This web search service is supported by Google Inc.

totop

Laisser un message